27
If on maximally
tolerated statin and
LDL-C ≥70 mg/dL,
adding ezetimibe*
can be beneficial
(2a)
Dashed arrow
indicates
RCT-supported
efficacy but
is less cost-
effective
Very High Risk
If on maximally
tolerated statin and
LDL-C <100 mg/dL with
a persistent fasting TG
level of 150–499 mg/dL,
after addressing
secondary causes,
icosapent ethyl may be
considered
(2b)
If judged to be on maximal LDL-C
lowering therapy and LDL-C ≥70 mg/dL,
or non-HDL-C ≥100 mg/dL, a PCSK9* mAb
can be beneficial
(2a)
High-intensity or maximal statin
(1)
